AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a Phase Ib clinical study titled A Phase Ib Open Label Positron Emission Tomography Study to Assess Changes in Intestinal [11C]AZ14132516 Uptake Following Administration of Multiple Doses of AZD7798 to Patients With Crohn’s Disease. The study aims to evaluate changes in intestinal uptake of the radioligand [11C]AZ14132516 after administering multiple doses of AZD7798 to patients with Crohn’s disease, which could provide insights into the drug’s effectiveness and safety.
The intervention involves the experimental drug AZD7798 and the radiopharmaceutical [11C]AZ14132516. AZD7798 is administered to study participants, while [11C]AZ14132516 is used in small doses for PET imaging to track changes in intestinal uptake.
This interventional study follows a sequential intervention model with no masking, meaning all participants and researchers know the treatments being administered. The primary purpose is to assess treatment effects in patients with Crohn’s disease.
The study began on October 16, 2024, and the latest update was submitted on August 20, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.
The study’s progress could influence AstraZeneca’s stock performance and investor sentiment, especially if the results indicate positive outcomes for Crohn’s disease treatment. This could also affect the competitive landscape, as advancements in treatment options may shift market dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.